Skip to main content
DANVILLE, Pa. – Geisinger announced today a new multi-year partnership with Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The collaboration aims to use the power of machine learning and artificial intelligence to build new precision medicine tools for cardiology that will enable the prediction of dangerous cardiac events and diseases before they occur, allowing for potentially life-saving intervention.

The partnership leverages the unique strengths of the two companies by establishing a foundation for Geisinger’s decades worth of clinical data to be analyzed by Tempus’ proprietary machine learning technology. The collaboration will reside within Geisinger as part of its Cardiac Imaging and Technology Laboratory, which is co-directed by Brandon Fornwalt, M.D., Ph.D. and Christopher Haggerty, Ph.D. Through strategic investment into machine learning, their team of engineers, researchers and physician scientists have been responsible for several projects that are already leveraging artificial intelligence and machine learning to positively impact patient care. 

By utilizing a clinical data structuring engine, Tempus is able to use its proprietary technology to analyze a combination of data points from various sources to track outcome and response data that can lead to more proactive cardiovascular treatments and interventions. Through this new partnership with Geisinger, Tempus is expanding its scope beyond oncology to advance precision medicine solutions for patients with cardiovascular disease. 

“Geisinger has a long history of innovation when it comes to assembling novel datasets to improve patient care,” said Eric Lefkofsky, Founder and CEO of Tempus. “We are thrilled to be collaborating with them to bring the power of technology and artificial intelligence to cardiology.”

“Our mission is to improve the lives of patients with cardiovascular disease through the development and application of state-of-the-art technologies,” said Dr. Fornwalt. “Tempus is one of the best in the business at building and translating these kinds of technologies, so we are very excited to work with them. This collaboration brings together complementary areas of expertise unified behind a joint vision of integrating the best technology available to positively impact our patients.”


About Tempus
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful, in an effort to bring the power of artificial intelligence to healthcare.  We enable physicians to make real time, data driven decisions and deliver personalized care for patients through our interactive analytical and machine learning platform. Our goal is for each patient to benefit from the treatment of others who came before by providing the health care industry with tools that learn as we gather more data. For more information, visit tempus.com.

About Geisinger

Geisinger is committed to making better health easier for the more than 1.5 million consumers it serves. Founded more than 100 years ago by Abigail Geisinger, the system now includes 13 hospital campuses, a 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. With 32,000 employees and 1,800 employed physicians, Geisinger boosts its hometown economies in Pennsylvania and New Jersey by billions of dollars annually. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.

geisinger placeholder


For media inquires:

Matthew Van Stone
Media Relations Director

570-808-3344
mrvanstone1@geisinger.edu